|
|
|
|
|
22.05.26 - 05:30
|
NervGen Announces Pricing of US$60.0 Million Public Offering of Securities (GlobeNewswire EN)
|
|
|
VANCOUVER, British Columbia, May 21, 2026 (GLOBE NEWSWIRE) -- NervGen Pharma Corp. (“NervGen” or the “Company") (NASDAQ: NGEN), a clinical-stage biopharmaceutical company developing first-in-class neuroreparative therapeutics for spinal cord injury and other neurotraumatic and neurologic conditions, today announced the pricing of an underwritten public offering of 24,000,000 common shares and accompanying warrants to purchase up to 24,000,000 common shares. The common shares are being sold at a public offering price of US$2.50 per common share and accompanying warrant. Each accompanying warrant has an exercise price of US$3.68 per common share, and will be immediately exercisable from the date of issuance, and will expire five years from the date of issuance....
|
|
|
|
|
21.05.26 - 22:03
|
NervGen Announces Proposed Public Offering of Securities (GlobeNewswire EN)
|
|
|
VANCOUVER, British Columbia, May 21, 2026 (GLOBE NEWSWIRE) -- NervGen Pharma Corp. (“NervGen” or the “Company") (NASDAQ: NGEN), a clinical-stage biopharmaceutical company developing first-in-class neuroreparative therapeutics for spinal cord injury and other neurotraumatic and neurologic conditions, today announced that it has commenced an underwritten public offering of common shares and accompanying warrants to purchase common shares and, in lieu of common shares to certain investors, pre-funded warrants to purchase common shares and accompanying warrants to purchase common shares. The closing of the offering will be subject to customary closing conditions. All of the common shares, pre-funded warrants and accompanying common share warrants to be sold in the offering will be offered by NervGen....
|
|
|
18.05.26 - 13:18
|
NervGen Reports First Quarter 2026 Financial Results and Provides Business Updates (GlobeNewswire EN)
|
|
|
VANCOUVER, British Columbia, May 18, 2026 (GLOBE NEWSWIRE) -- NervGen Pharma Corp. (“NervGen” or the “Company") (NASDAQ: NGEN), a clinical-stage biopharmaceutical company developing first-in-class neuroreparative therapeutics for spinal cord injury (SCI) and other neurotraumatic and neurologic conditions, today reported financial results for the first quarter ended March 31, 2026, and provided business updates....
|
|
|
27.04.26 - 13:33
|
NervGen Pharma Strengthens Leadership Team with Appointment of Keith Vendola as Chief Financial Officer (GlobeNewswire EN)
|
|
|
VANCOUVER, British Columbia, April 27, 2026 (GLOBE NEWSWIRE) -- NervGen Pharma Corp. (“NervGen” or the “Company") (NASDAQ: NGEN), a clinical-stage biopharmaceutical company developing first-in-class neuroreparative therapeutics for spinal cord injury (SCI) and other neurotraumatic and neurologic conditions, today announced the appointment of Keith Vendola, MD, MBA, as Chief Financial Officer (CFO), effective immediately. Dr. Vendola will lead the Company's financial strategy and operations, including capital markets activity, financial planning, corporate development and supporting strategic initiatives....
|
|
|
13.04.26 - 13:48
|
NervGen Pharma to Participate in the H.C. Wainwright "HCW@Home" Series and the 2026 Bloom Burton & Co. Healthcare Investor Conference (GlobeNewswire EN)
|
|
|
VANCOUVER, British Columbia, April 13, 2026 (GLOBE NEWSWIRE) -- NervGen Pharma Corp. (“NervGen” or the “Company") (NASDAQ: NGEN), a clinical-stage biopharmaceutical company developing first-in-class neuroreparative therapeutics for spinal cord injury (SCI) and other neurotraumatic and neurologic conditions, today announced that Adam Rogers, MD, President and Chief Executive Officer of NervGen, and other members of the Company's executive leadership team, are scheduled to participate in the H.C. Wainwright “HCW@Home” series and the 2026 Bloom Burton & Co. Healthcare Investor Conference....
|
|
|
|
|
|
|
31.03.26 - 15:12
|
XFRA: 9UA: Wiederaufnahme/Resumption (XETRA)
|
|
|
FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.
THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:
INSTRUMENT NAME KUERZEL/SHORTCODE ISIN
NERVGEN PHARMA CORP. 9UA CA64082X2032
AB/FROM ONWARDS 31.03.2026 15:02 CET...
|
|
|
|
|
17.03.26 - 08:06
|
XFRA: 9UA: Aussetzung/Suspension (XETRA)
|
|
|
DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:
THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:
INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTIL
NERVGEN PHARMA CORP. 9UA CA64082X2032 BAW/UFN...
|
|
|
12.03.26 - 21:18
|
NervGen Pharma Announces Voluntary Delisting from TSX Venture Exchange (GlobeNewswire EN)
|
|
|
VANCOUVER, British Columbia, March 12, 2026 (GLOBE NEWSWIRE) -- NervGen Pharma Corp. (“NervGen” or the “Company") (TSXV: NGEN) (NASDAQ: NGEN), a clinical-stage biopharmaceutical company developing first-in-class neuroreparative therapeutics for spinal cord injury (SCI) and other neurotraumatic and neurologic conditions, today announced that the Company has elected to voluntarily delist its common shares from TSX Venture Exchange (“TSXV”), effective at the close of markets on March 16, 2026....
|
|
|
|
|
23.02.26 - 09:51
|
XFRA: MWBMU - HANDELSUNTERBRECHUNG - TEIL 4 (XETRA)
|
|
|
CA57808L3056
JP3801600002
GG00BMB5XZ39
US05875B3042
GB00BL97B504
CA92540L1076
CA04271V1058
GB00BN7JZR28
AU0000157075
PLAQUA000014
GB0001646941
CA31866G1028
KYG8116R1074
CA64082X2032
IT0005439861
JP3756200006
IT0005433765
PLDTLGM00019
PLCCTLS00017
SE0013382066
PLCNSLB00012
BE0974374069
US5632457033
KYG9482E1180
US04681Y1038
PLSNKTK00019
CNE100006M66
CA42804X3058
US3131488682
US3131488435
SE0000395428
FI4000592159
CA02255Q2099
IT0005531238
CA37895W1095
CA0029471095
AU0000284895
SGXE32143393
JP3049110004
SGXE32247038
US29081P2048
US0126532003
US00654J2069
CA0213618865
SE0009242175
AU000000ASX7
CNE1000001Y8
MHY3130D1013
GB00B95L0551
KYG9560F1028
KYG464401143
US6294442099
CA38154G1081
KYG4914A1076
CNE100007F98
US94858P2092
KYG1331C1042
US05969A1051
GRS001003052
US0970232049
US09260U1097
ARP125991090
US0773472016
AU0000153215
CNE100000551
SE0015961594
CNE100000254
US0905721082
IT0005468357
US09075P2048
GRS246003008
NZCENE0001S6
US05070F3082...
|
|
|
18.02.26 - 13:33
|
NervGen Pharma to Participate at Upcoming Investor Conferences (GlobeNewswire EN)
|
|
|
VANCOUVER, British Columbia, Feb. 18, 2026 (GLOBE NEWSWIRE) -- NervGen Pharma Corp. (“NervGen” or the “Company") (TSXV: NGEN) (NASDAQ: NGEN), a clinical-stage biopharmaceutical company developing first-in-class neuroreparative therapeutics for spinal cord injury (SCI) and other neurotraumatic and neurologic conditions, today announced that Adam Rogers, MD, President and Chief Executive Officer of NervGen, and other members of the Company's executive leadership team, are scheduled to participate at multiple upcoming investor conferences....
|
|
|
|
|
12.02.26 - 22:18
|
NervGen Pharma Announces Retirement of Chief Financial Officer, Bill Adams (GlobeNewswire EN)
|
|
|
VANCOUVER, British Columbia, Feb. 12, 2026 (GLOBE NEWSWIRE) -- NervGen Pharma Corp. (“NervGen” or the “Company") (TSXV: NGEN) (NASDAQ: NGEN), a clinical-stage biopharmaceutical company developing first-in-class neuroreparative therapeutics for spinal cord injury (SCI) and other neurotraumatic and neurologic conditions, today announced that Bill Adams will retire as Chief Financial Officer, effective March 15th, 2026. The Company has engaged a leading executive search firm to identify a successor, and Mr. Adams will continue in an advisory capacity following his retirement date to support the transition....
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
